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14α-demethylase (CYP51) of human pathogens
Jasmine Warfield1, William N Setzer2 and Ifedayo Victor Ogungbe1*Abstract
Sterol 14α-demethylase is a validated and an attractive drug target in human protozoan parasites. Pharmacological
inactivation of this important enzyme has proven very effective against fungal infections, and it is a target that is
being exploited for new antitrypanosomal and antileishmanial chemotherapy. We have used in silico calculations to
identify previously reported antiparasitic sterol-like compounds and their structural congeners that have preferential
and high docking affinity for CYP51. The sterol 14α-demethylase from Trypanosoma cruzi and Leishmania infantum,
in particular, preferentially dock to taraxerol, epi-oleanolic acid, and α/β-amyrim structural scaffolds. These structural
information and predicted interactions can be exploited for fragment/structure-based antiprotozoal drug design.
Keywords: Protozoa; Docking; Sterol 14α-demethylase; Sterols; AntiparasiticIntroduction
Sterol 14α-demethylase (CYP51), a cytochrome P450
mixed-function oxidase, is involved in the biosynthesis of
numerous structurally similar sterols in animals, fungi,
plants and protozoans. Several of these sterols serve as im-
portant component of cell membranes, and they are vital
to the maintenance of cellular structural integrity in those
organisms. Some derivatives of plant sterols also function
as signaling molecules, and as antifungal agents (Rozhon
et al. 2013; Geisler et al. 2013; Qi et al. 2006). CYP51 is a
well-known druggable target in fungi. Several generations
of azole-based CYP51 inhibitors have already been devel-
oped as clinical antifungal drugs (Peng et al. 2013). The
specificity of these azole-based drugs for fungal CYP51
has been linked to the low sequence identity between the
fungal enzyme and mammalian CYP51 (Aoyama 2005).
The sterol 14α-demethylases in Trypanosoma cruzi,Trypa-
nosoma brucei, Leishmania infantum and Mycobacterium
tuberculosis have also been studied as potential targets for
drug discovery and development. Although the apparent
lack of de novo sterol biosynthesis in M. tuberculosis, and
the fact that other mycobacteria cytochrome P450s like
CYP121 are more sensitive to azole drugs makes CYP51 a
less desirable drug target in that organism (Cole et al.* Correspondence: Ifedayo.v.ogungbe@jsums.edu
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in any medium, provided the original work is p1998; McLean et al. 2002). Protozoans, on the other hand,
especially Trypanosoma cruzi and Leishmania infantum,
have been widely reported to be susceptible to chemotypes
targeting CYP51 (Urbina et al. 1996; Buckner et al. 2012;
Lorente et al. 2004; Doyle et al. 2010; Gunatilleke et al.
2012). Drug discovery targeting CYP51 remains one of
the active areas of antitrypanosomal research. Identifying
chemotypes via in-silico screening and subsequent phenotype-
based in-vitro validation has become the bedrock of mod-
ern small molecule drug discovery. Our previous works
involving virtual screening of antitrypanosomal natural
products libraries against protozoan drug targets revealed
that antitrypanosomal sterol–type compounds have high
affinity for CYP51 as illustrated with a few drug targets in
Figure 1 (Ogungbe and Setzer 2013; Setzer and Ogungbe
2012). It can be speculated that the predicted affinities is
because of the structural compatibility between the sterol-
like compounds and CYP51. The objective of this work is
to identify antiparasitic compounds and their structural
congeners that display selectivity for protozoal sterol 14α-
demethylase, in silico, and on which structure- or shape-
based analogues or potential drug leads can be designed
or identified.Material and methods
Compound and protein structure preparation
Ligands used for this study were geometry optimized
using the molecular mechanics force field (MMFF)an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.



























Figure 1 Docking energies (re-rank score) of antiparasitic sterols in L. infantum drug targets (Sterol 14α demethylase (CYP51),
glyoxalase II (GLO2), thiol-dependent reductase I (TDR1), trypanothione reductase (TR). The figure shows the selectivity of sterol-like
compounds for CYP51. One—way ANOVA followed by Tukey’s multiple comparison test suggest statistically significant difference between the
means of all groups (P < 0.0001).
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studies were carried out using the crystal structures of
T. cruzi CYP51 (PDB Id: 3khm, 3zg2, 4h6O (Lepesheva
et al. 2010; Hargrove et al. 2013; Andriani et al. 2013)),
T. brucei CYP51 (PDB Id: 3g1q, 3gw9, 4g3j (Hargrove
et al)), M. tuberculosis CYP51 (PBD Id: 2ci0, 2w0a
(Chen et al. 2009; Podust et al. 2007)), L. infantum
CYP51 (PBD Id: 3l4d (Hargrove et al. 2011)), and H.
sapiens CYP51 (3jus, 3juv, 3ld6 (Strushkevich and Usanov
2014; Strushkevich et al. 2010)) from the RCSB Protein
Data Bank. The protein structures were used as rigid
model structures, no relaxation was performed and as-
signments of ionic charges on each protein structure
were based on standard protonation states and the default
templates of Molegro Virtual Docker (2011b; Thomsen
and Christensen 2006). The similarity search was carried
out using the default sub-structure similarity search en-
gine of the Dictionary of Natural Products (2013). Statisiti-
cal comparison was carried using GraphPad Prism.
Docking simulation and scoring
Flexible ligand models were used for docking and post-
docking geometry optimizations. The post-docking
geometry optimizations were carried out using the
Nelder-Mead Simplex method in Molegro Virtual
Docker. Simulations were carried out using the sub-
strate binding site of CYP51. A docking sphere (15 Å ra-
dius) was placed on the binding sites of each protein
structure in order to allow different orientations of each
ligand to be searched in the binding cavities and
for multiple protein-ligand poses to be returned. TheRMSD threshold for multiple cluster poses was set at
<1.00 Å. The docking algorithm was set at maximum it-
erations of 1500 with a simplex evolution population
size of 50 and a minimum of 30 runs for each ligand.
Each binding site of oligomeric structures was searched,
and the lowest energy pose (based on the re-rank scores)
for each ligand across all protein structures are presented
in Additional file 1: Table S1–S5. The docking scores of
known CYP51 inhibitors N-1-(2,4-dichlorophenyl)-2-(1H-
imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadi-azol-2-yl)ben-
zamide and ketoconazole are presented in Additional file 1:
Table S6, and PDB files of CYP51-ligand complexes dis-
cussed in this article are provided as Additional file 2 in the
supporting information.
Results and discussion
Antitrypanosomal sterols have high affinity for H. sapiens
CYP51 in silico
From our previous work on T. brucei and L. infantum
drug targets (Ogungbe and Setzer 2013; Setzer and
Ogungbe 2012), we proposed that structural compatibil-
ity dictates the molecular recognition between antitrypa-
nosomal sterol–type compounds and CYP51. The first
aim of this work was to identify compounds that are se-
lective for trypanosomal CYP51s in silico. This was ac-
complished via a comparative docking analysis involving
137 sterol-like antiparasitic natural products and the
sterol 14α-demethylase from T. brucei, T. cruzi, M. tu-
berculosis, L. infantum and H. sapiens. The result of the
simulations is presented in Additional file 1: Figure 1
and Table S1. The results show that about 50 percent of
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to the human CYP51. The top-five compounds for
H. sapiens CYP51 are 3-acetylkhayalactone, carapolide A,
gedunin, grandifolide A and swietenine (Docking energies
are −142.12, −130.87, −128.70, −128.36 and −128.02 kJ/mol,
respectively). 3-Acetylkhayalactone was predicted to bind
favourably in a 157.70 Å3 cavity distal from the substrate
binding site. The other four compounds were predicted to
bind at the substrate binding site. Visual inspection reveals
that they overlap with the co-crystallized ligand ketocona-
zole. The strongest docking poses of carapolide A and
ketoconazole are shown in Figure 2. Some of the target
residues for the limonoid carapolide A are Ala 311, Gly
307, Ile 377 and 488, Tyr 131 and 145, Thr 135, 315 and
318, and Phe 234. Most of those residues have been re-
ported to participate in the interactions between human
CYP51 and antifungal azoles (Strushkevich et al. 2010).
Substructure similarity search for selective sterols
A number of compounds studied were selective for
T. cruzi CYP51. These include 20-epi-isoiguesterinol,
isoiguesterin, khivorin, procerin, taraxerol, ursolic acid
as well as α- and β-amyrin. Physalin K and procerin
were selective for T. brucei CYP51. 7-Deacetylkhivorin
was selective for M. tuberculosis CYP51 while 1-O-
acetylkhayanolide B, physalin V, saringosterol and epi-
oleanolic acid were selective for L. infantum CYP51
(Figure 3 and Table 1). A substructure similarity search
was carried out for compounds that displayed selectivityFigure 2 The lowest energy docking poses of carapolide A (Orange) a
CYP51. Hydrogen bonding interaction between ketoconazole and Tyr 145
to interact with the amino acid residues shown. The molecular surface diagtowards CYP51 from T. brucei, T. cruzi, and L. infan-
tum. This was carried out in order to identify sterol-like
natural products that have strong docking affinities for
CYP51s, and that can be evaluated as potential CYP51
inhibitors. We used the Dictionary of Natural Products
DNP (2013) as a reference for those structures. From
the similarity search, nine compounds were found to be
structurally-related to 20-epi-isoiguesterinol and isoi-
guesterin. Out of the nine, eight are isomers of celas-
trol. The other compound was excelsine. The docking
re-rank scores of those compounds, however, were less
or about the same as those of 20-epi-isoiguesterinol
and isoiguesterin for T. cruzi CYP51 (Additional file 1:
Table S2).
In the case of khivorin, 7-deacetylkhivorin, physalin K
and V, and 1-O-acetylkhayanolide B, all the structurally-
related compounds found in the DNP were part of our
original compound dataset while the structurally com-
plex limonoid procerin lacks any structural congener.
Seventy-nine and 304 compounds were found to share
substructural similarity with taraxerol and ursolic acid, re-
spectively. Several of the 79 taraxerol structural congeners
have high docking affinity for T. cruzi CYP51. These in-
clude the hexadecanoyl derivative of 11,12-oxidotaraxerol,
the 2,3-bis-(4-hydroxybenzoyl) derivative of sebiferenic
acid, the 3-O-(E)-p-coumarate derivative of aleuritolic
acid in addition to crassifoate and 3-caffeoylisomyricadiol
(Figure 4 and Additional file 1: Table S3). The structural
congeners of ursolic acid that have high docking affinitynd ketoconazole (Blue) in the substrate binding site of human
is depicted with the blue dash lines. Both compounds were predicted
ram is shown in Additional file 1: Figure S2.
Figure 3 Structures of antiparasitic sterol-like compounds that show preferential docking to T. cruzi-, T. brucei-, L. infantum-, and M.
tuberculosis CYP51.
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dihydroxy-12-ursen-28-oic acid, 3-(Z)-feruloyl corosolic
acid, 3-(E)-caffeoyl corosolic acid, 3-(Z)-caffeoyl corosolic
acid and 2-(E)-feruloyl corosolic (Figure 4 and Additional
file 1: Table S4). In the case of epi-oleanolic acid, α-
amyrin, and β-amyrin, 1213 structural congeners were
obtained and those compounds were used for docking
simulations with T. cruzi CYP51 and L. infantum CYP51.
Our result shows that β-amyrin eicosanoate, β-amyrin
stearate and β-amyrin behenate as well as, β-amyrin lino-
leate and β-amyrin-palmitoleate have the top dockingTable 1 Docking scores of selective antiparasitic agents for C
Antitrypanosomal agents
T. cruzi T. brucei




Physalin K −6.4 −112.1




Ursolic acid −110.9 −79.5
α-Amyrin −102.4 −80.2
β-Amyrin −104.8 −79.5
epi-Oleanolic acid −37.0 −95.5
Isoiguesterin −94.0 −85.5
The bold numbers indicates the lowest docking score for each compound.affinities for T. cruzi CYP51 (Figure 4 and Additional file 1:
Table S5). For L. infantum CYP51; maniladiol stearate,
erythrodiol 3-stearate, asprellic acid B, the 2-O-caffeate
derivative of maslinic acid, and the 3-O-caffeate derivative
of 20-epikatonic acid have the top docking affinities
(Figure 4 and Additional file 1: Table S5).
Taraxerol structural congeners and T. cruzi CYP51
The triterpene taraxerol has been reported to have
moderate antitrypanosomal and antiplasmodial activity
(IC50 = 10.5 μM for T. brucei rhodesiense and 8.5 μM forYP51
CYP51















Figure 4 Structures of sterol derivatives that were selective for T. cruzi and L. infantum CYP51.
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unable to find any record of its biological activity
against T. cruzi in the literature. The top structural
congeners of taraxerol from the calculations are 3-
hexadecanoyl 11,12-oxidotaraxerol and crassifoate.
These compounds were isolated from the leaves of Ery-
throxylum passerinum and Nepeta crassifolia, respect-
ively (Barreiros et al. 2002; Ibrahim and Ali 2007). The
high docking energies of these compounds for T. cruzi
CYP51 can be attributed to their relative bulkiness and
shape. The orientation of the compounds in the sub-
strate binding site of T. cruzi CYP51 is also atypical ofsterols. Their long hydrophobic lipid moieties are in
close proximity with the heme cofactor, while their
triterpene-structural moieties occupies the hydrophobic
access channel of the binding site. This is similar to what
has been reported for the extended arm of posaconazole
(Lepesheva et al. 2010) although structural model of
CYP51 co-crystallized with fatty acid ester of any sterol is
yet to be reported. It would be of particular importance to
determine the orientation(s) of fatty acid esters of sterols
in the CYP51 binding cavity experimentally. Nevertheless,
the shape that the two compounds adopt in the theoretical
models can be used to design similar-shaped compounds
Figure 5 The lowest energy pose of 3-hexadecanoyl 11,12-oxidotaraxerol (yellow) and crassifoate (blue) in the active site of T. cruzi
CYP51. The hydrophobic amino acid residues in the active site offer a favorable binding patch for the esterified sterols. The molecular surface
diagram is shown in Additional file 1: Figure S3.
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addition to elongated hydrophobic moieties like in the
case of posaconazole.
The triterpene-structural moiety of 3-hexadecanoyl
11,12-oxidotaraxerol is predicted to interact with Met
460, Gly 49, Pro 210, Val 213 and Val 102 residues in
the hydrophobic channel of the substrate binding site
(Figure 5). The 3-O-caffeate derivative of isomyricadiol
was predicted to have hydrogen bonding interactions
with residues Tyr 103 and Met 358. It has favourable
steric interactions with Ala 291, Met 284, Ala 115, Met
106, Ile 105 and Met 358 and 360. In the case of the 2,3-
bis-(4-hydroxybenzoyl) derivative of sebiferenic acid, it
has favorable steric interactions with Met 460, Tyr 116,
Ala 115 and 291, Leu 356 and Val 213 in addition to
hydrogen bonding interactions with Tyr 116 and the two
propionic acid moiety of the heme co-factor as shown in
Figure 6 while the lowest energy pose of the 3-O-p-coumarate derivative of aleuritolic acid have 460, Tyr
103 and 457, as well as an hydrogen bonding interaction
with Ile 209.
epi-Oleanolic acid structural congeners and L. infantum CYP51
Several derivatives of oleanolic acid including epi-olea-
nolic acid have been reported to have weak to moderate
antiprotozoal activities (Schmidt et al. 2012), however,
the molecular targets or the mechanism(s) of action of
these compounds are yet to be described. The results
from this work showed that epi-oleanolic acid and a
number of its congener have high docking affinities for
L. infantum CYP51 relative to other antiparasitic sterols.
In a similar fashion to taraxerol derivatives described
above, the structural congeners of epi-oleanolic acids
that have high docking affinity for L. infantum CYP51
possess either long hydrophobic tails or hydroxycinna-
moyl groups (Figure 4 and Additional file 1: Table S5).
Figure 6 The lowest energy pose of 2,3-bis-(4-hydroxybenzoyl) derivative of sebiferenic acid is predicted to interact via hydrogen
bonding with the heme co-factor in the active site of T. cruzi CYP51. The hydrophobic amino acid residues in the active site offer a
favorable binding patch for esterified sterols. The molecular surface diagram is shown in Additional file 1: Figure S4.
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hydrogen bond with Ala 290, and they also have exten-
sive steric interactions with the heme-cofactor (Figures 7
and 8). The 2-O-caffeate derivative of maslinic acid was
predicted to have significant interactions (in terms of en-
ergy values) with Leu 355, Met 357 and Met 359, Phe
48, Tyr 102, and Val 356. Similarly, the 3-O-caffeate de-
rivative of 20-epikatonic acid has significant interactions
with Leu 355, Met 357 and 459, Phe 48, and Val 356. In
the case of the asprellic acid B, the free acid group at
position 28 was predicted to hydrogen bond with the
heme co-factor while the caffeoyl moieties hydrogen
bond with Ala 286 and His 457 (Figure 9). Cinnamateesters or hydroxycinnamates have not been reported to
have inhibitory activity against CYP51. However, similar
motifs have been reported to inhibit Cochliobolus luna-
tus benzoate hydroxylate (CYP53) (Korošec et al. 2014).
α/β-amyrin structural congeners and T. cruzi CYP51
The ubiquitous pentacyclic triterpenes α- and β-amyrin,
as well as, their derivatives have been reported to exhibit
antiprotozoal activities, amongst many other biological ac-
tivities (Hoet et al. 2007; Mwangi et al. 2010; Schinor et al.
2007). However, they have not been reported to inhibit
sterol 14α demethylase. In fact, the multifunctional cyto-
chrome P450 AsCYP51H10 in Oats (Avena spp) has been
Figure 7 Geometry-optimized pose of 2-O-caffeoyl maslinic acid. The blue dash arrow represents hydrogen bonding interactions while the
blue sphere on the residues denotes level of solvent exposure. Hydrophobic residues are olive green while polar residues are depicted as pink.
The purple circles on the atoms/functional groups represent solvent exposure. The molecular surface diagram is shown in Additional file 1:
Figure S5.
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amyrin. The structural congeners of β-amyrin that have
high affinity for T. cruzi CYP51 include β-amyrin eicosano-
ate, β-amyrin stearate, β-amyrin behenate, β-amyrin lineolate
and β-amyrin palmitoleate. The sterol motif of those com-
pounds was predicted to interact with similar residues in
the TcCYP51 active site. These residues include Met 358
and 460, Leu 356, Ala 287, Tyr 103 and Lys 368. There isFigure 8 Geometry-optimized pose of 3-O-caffeoyl-20-epikatonic acid
the blue sphere on the residues denotes level of solvent exposure. Hydrop
pink. The purple circles on the atoms/functional groups represent solvent e
Figure S6.an exact spatial overlap of the sterol motif in the docking
poses of the five lowest-energy fatty esters of β-amyrin (as
shown in Figure 10) and steric interactions is the most
predominate interactions predicted between T. cruzi
CYP51 and these fatty esters. The hydrophobic tail of
β-amyrin eicosanoate was predicted to adopt a kink con-
formation and was predicted to have steric interactions
with His 468.. The blue dash arrow represents hydrogen bonding interactions while
hobic residues are olive green while polar residues are depicted as




Figure 9 The lowest energy pose of asprellic acid B. Hydrogen bonding interactions with Tyr 102, Ala 286, heme-cofactor and His 457 are
predicted as blue dash lines. The molecular surface diagram is shown in Additional file 1: Figure S7.
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The important findings from this work are 1) majority of
antiparasitic sterol-like compounds preferentially dock
to the human CYP51, perhaps, this is due to the rela-
tively large size of its active site, 2) taraxerol, α/β-amyrin
and a number of their fatty acyl esters and cinnamate
derivatives have preferential affinity for T. cruzi’s CYP51,
3) epi-oleanolic and its hydroxycinnamate derivatives
have high docking affinities for L. infantum’s CYP51.
Those predictions can be validated experimentally and
used as guide for future natural products or synthetic
chemistry target-based (CYP51) drug discovery. It is im-
portant to note that, generally, docking scores from mul-
tiple crystallographic structures of the same protein tendAla 287
Heme co-factor
Figure 10 The top five structural congeners of β-Amyrin. An overlay o
with Ala 287 and Met 358. The molecular surface diagram is shown in Addto be similar. But, we also noticed that a significant
number of compounds have substantially different scores
in similar subunits of oligomeric structures. This is per-
haps due to protein flexibility captured in the crystallo-
graphic structures. These subtle differences in protein
structures perhaps result in prediction of interactions
between the small molecules and different amino acid
residues in the binding sites of similar subunits of oligo-
meric proteins. Also, it has not escaped us that the com-
pounds identified from the simulations can also serve as
substrates for any of the CYP51s and that most of the
compounds we identified as potential inhibitors of
CYP51 in this work may not have ideal drug-like
ADMET (absorption, distribution, metabolism, excretionMet 358
f all five compounds shows that the sterol motif overlaps, and interacts
itional file 1: Figure S8.
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http://www.springerplus.com/content/3/1/679and toxicity) properties. However, structural optimization
can help to introduce functional groups that can serve as
inhibitory warheads and that can also improve ADMET
properties.
Additional files
Additional file 1: Docking (MVD re-rank) scores of antiparasitic
sterols and CYP51.
Additional file 2: PDB files of CYP51-ligand complexes.
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